Entera Bio Ltd. (ENTX) Reports $15.6M Q3 Net Loss; Cash Expected to Fund Program Through 2030
Entera Bio (ENTX) reported a Q3 2026 net loss of $15.6M, wider than the $3.2M loss a year earlier, including a $7.5M non-cash warrant remeasurement. The company had $265.9M in cash and expects funds to last through 2030, supporting its EB613 program and operations.
How this was made

The 30-second read
Why it matters
The earnings miss may depress the stock in the short term, but the sizable cash balance and upcoming trial could mitigate long‑term risk.
Market read
First‑time earnings disclosure for a micro‑cap biotech; provides new data for traders.
What to watch
Potential upside from upcoming EB613 Phase 3 trial and NDA filing timeline.
Background
Entera Bio reported its Q3 2026 financial results, highlighting a net loss and cash position while preparing for a Phase 3 trial of EB613.
Ticker impact
Q3 2026 net loss of $15.6M and cash balance of $265.9M disclosed for the first time.
likely pressure as investors price in the larger loss despite ample cash.
Earnings release provides fresh financial metrics; loss magnitude exceeds prior year and market typically reacts negatively to widening losses.
Market effects
Biotech sector may see modest pullback as earnings miss expectations.
US biotech investors may adjust exposure.
Limited; primarily affects Entera and peers.
Counterpoint
Cash runway to 2030 could support upside if Phase 3 data are positive.
Key entities
- companyEntera Bio Ltd.
Biotech firm developing EB613.

